Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAP2 | P11137 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076318 | 0.87 | KMT2A (0.55) | PARP1IKBKBCHUKFFAR1MEN1 | |
| SCHEMBL5076477 | 0.84 | PARP1 (0.56) | PARP1MEN1ALDH1A1KMT2AHDAC11 | |
| SCHEMBL5074027 | 0.84 | PARP1 (0.49) | PARP1IKBKBALDH1A1MAP2HDAC11 | |
| SCHEMBL5074311 | 0.83 | HPGD (0.58) | PARP1MEN1ALDH1A1KMT2ATHRB | |
| SCHEMBL5077303 | 0.83 | CDC7 (0.53) | PARP1MEN1ALDH1A1KMT2AHDAC11 | |
| SCHEMBL5074225 | 0.83 | BRD4 (0.54) | PARP1IKBKBALDH1A1MAP2HDAC11 | |
| SCHEMBL5074291 | 0.80 | PARP1 (0.60) | PARP1JAK2HDAC11 | |
| SCHEMBL5071957 | 0.80 | PARP1 (0.60) | PARP1MEN1ALDH1A1KMT2ATHRB | |
| SCHEMBL5074054 | 0.80 | EGFR (0.42) | PARP1HDAC11BRD4 | |
| SCHEMBL5077305 | 0.80 | PARP1 (0.53) | PARP1ALDH1A1HDAC11BTKBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7087637-B2 | Substituted indoles which are PARP inhibitors | BASF AG (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885DHFR 2483/4885IKBKB 153/4885 |
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | PARP1, PARP2, PARP12 | PARP1 1/4885DHFR 398/4885IKBKB 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.